Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells

Stem Cells

Volumn 31, Issue 2, 2013, Pages 317-326

  Nystedt, Johanna ^a   Anderson, Heidi ^a   Tikkanen, Jonne ^a   Pietila, Mika ^b   Hirvonen, Tia ^a   Takalo, Reijo ^b,c   Heiskanen, Annamari ^a   Satomaa, Tero ^a,b   Natunen, Suvi ^a   Lehtonen, Siri ^a   Hakkarainen, Tanja ^b,c   Korhonen, Matti ^d   Laitinen, Saara ^a   Valmu, Leena ^a   Lehenkari, Petri ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d GLYKOS FINLAND LTD   (Finland)

Author keywords

Biodistribution; Cell adherence; Cell surface; Lung; Mesenchymal stromal stem cell; Systemic infusion

Indexed keywords

ALPHA4 INTEGRIN; ALPHA6 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; FIBRONECTIN; SCATTER FACTOR RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 6;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL COUNT; CELL SIZE; CELL STRUCTURE; CELL SURFACE; CELL THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FUCOSYLATION; HUMAN; HUMAN TISSUE; LUNG CAPILLARY; LUNG CLEARANCE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL ADHESION; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; FETAL BLOOD; GENE EXPRESSION; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHA4; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHA6; INTEGRIN ALPHA6BETA1; ISOTOPE LABELING; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; TECHNETIUM COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874342825     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1271     Document Type: Article

References (50)

1. Phinney DG, Prockop DJ Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007;25:2896-2902. (Pubitemid 350127874)
2. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009;4:206-216.
3. Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20. (Pubitemid 32437040)
4. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003; 108:863-868. (Pubitemid 37022130)
5. Allers C, Sierralta WD, Neubauer S et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004;78: 503-508. (Pubitemid 39097094)
6. Tolar J, O'shaughnessy MJ, Panoskaltsis-Mortari A et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 2006;107:4182-4188. (Pubitemid 43726831)
7. Hakkarainen T, Sarkioja M, Lehenkari P et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007;18:627-641. (Pubitemid 47187094)
8. Meyerrose TE, De Ugarte DA, Hofling AA et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 2007;25:220-227. (Pubitemid 46052993)
9. Schrepfer S, Deuse T, Reichenspurner H et al. Stem cell transplantation: The lung barrier. Transplant Proc 2007;39:573-576. (Pubitemid 46386222)
10. Vilalta M, Degano IR, Bago J et al. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev 2008;17:993-1003.
11. Fischer UM, Harting MT, Jimenez F et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009;18:683-692.
12. Kang WJ, Kang HJ, Kim HS et al. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006;47: 1295-1301.
13. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012;30: 1575-1578.
14. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci 2004;117:5655-5664. (Pubitemid 40012211)
15. Toma C, Wagner WR, Bowry S et al. Fate of culture-expanded mesenchymal stem cells in the microvasculature: In vivo observations of cell kinetics. Circ Res 2009;104:398-402.
16. Kuppen PJ, Marinelli A, Camps JA et al. Biodistribution of lymphokine- activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion. Int J Cancer 1992;52:266-270.
17. Makinen S, Kekarainen T, Nystedt J et al. Human umbilical cord blood cells do not improve sensorimotor or cognitive outcome following transient middle cerebral artery occlusion in rats. Brain Res 2006; 1123:207-215.
18. Nystedt J, Makinen S, Laine J et al. Human cord blood CD34 cells and behavioral recovery following focal cerebral ischemia in rats. Acta Neurobiol Exp (Wars) 2006;66:293-300. (Pubitemid 46114712)
19. Makela J, Anttila V, Ylitalo K et al. Acute homing of bone marrowderived mononuclear cells in intramyocardial vs. intracoronary transplantation. Scand Cardiovasc J 2009;43:366-373.
20. Leskela HV, Risteli J, Niskanen S et al. Osteoblast recruitment from stem cells does not decrease by age at late adulthood. Biochem Biophys Res Commun 2003;311:1008-1013. (Pubitemid 37393419)
21. Laitinen A, Nystedt J, Laitinen S. The isolation and culture of human cord blood-derived mesenchymal stem cells under low oxygen conditions. Methods Mol Biol 2011;698:63-73.
22. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317. (Pubitemid 44269669)
23. Lee RH, Seo MJ, Pulin AA et al. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009;113:816-826.
24. Hemmoranta H, Satomaa T, Blomqvist M et al. N-glycan structures and associated gene expression reflect the characteristic N-glycosylation pattern of human hematopoietic stem and progenitor cells. Exp Hematol 2007;35:1279-1292. (Pubitemid 47088781)
25. Lee JK, Lee MK, Jin HJ et al. Efficient intracytoplasmic labeling of human umbilical cord blood mesenchymal stromal cells with ferumoxides. Cell Transplant 2007;16:849-857.
26. Suila H, Pitkanen V, Hirvonen T et al. Are globoseries glycosphingolipids SSEA-3 and -4 markers for stem cells derived from human umbilical cord blood? J Mol Cell Biol 2011;3:99-107.
27. Heiskanen A, Hirvonen T, Salo H et al. Glycomics of bone marrowderived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. Glycoconj J 2009;26:367-384.
28. Mason C, Brindley DA, Culme-Seymour EJ et al. Cell therapy industry: Billion dollar global business with unlimited potential. Regen Med 2011;6:265-272.
29. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586. (Pubitemid 351626841)
30. Lee RH, Pulin AA, Seo MJ et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
31. Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin 2011;27:719-733.
32. Lee JW, Fang X, Krasnodembskaya A et al. Concise review: Mesenchymal stem cells for acute lung injury: Role of paracrine soluble factors. Stem Cells 2011;29:913-919.
33. Miettinen JA, Salonen RJ, Niemela M et al. Effects of intracoronary infusion of bone marrow-derived stem cells on pulmonary artery pressure and diastolic function after myocardial infarction. Int J Cardiol 2010;145:631-633.
34. Deak E, Ruster B, Keller L et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy 2010;12:260-264.
35. Chute JP. Stem cell homing. Curr Opin Hematol 2006;13:399-406. (Pubitemid 44607440)
36. Furlani D, Ugurlucan M, Ong L et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 2009;77:370-376.
37. Neuss S, Becher E, Woltje M et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004;22:405-414. (Pubitemid 38736624)
38. Bonig H, Priestley GV, Oehler V et al. Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol 2007;35:326-334. (Pubitemid 46135813)
39. Qian H, Tryggvason K, Jacobsen SE et al. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood 2006;107: 3503-3510.
40. Bonig H, Priestley GV, Wohlfahrt M et al. Blockade of alpha6-integrin reveals diversity in homing patterns among human, baboon, and murine cells. Stem Cells Dev 2009;18:839-844.
41. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003;10:228-241. (Pubitemid 36302404)
42. Silva WA, Jr., Covas DT, Panepucci RA et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003;21:661-669. (Pubitemid 37329159)
43. Brooke G, Tong H, Levesque JP et al. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 2008;17:929-940.
44. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008;26:2287-2299.
45. Pietila M, Palomaki S, Lehtonen S et al. Mitochondrial function and energy metabolism in umbilical cord blood- and bone marrow-derived mesenchymal stem cells. Stem Cells Dev 2012;21:575-588.
46. Xia L, McDaniel JM, Yago T et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004;104:3091-3096. (Pubitemid 39507123)
47. Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008;14:181-187. (Pubitemid 351214550)
48. Heiskanen A, Satomaa T, Tiitinen S et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202. (Pubitemid 46052991)
49. Satomaa T, Heiskanen A, Mikkola M et al. The N-glycome of human embryonic stem cells. BMC Cell Biol 2009;10:42.
50. Martinez C, Hofmann TJ, Marino R et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 2007;109: 4245-4248. (Pubitemid 46743389)